Search results
Showing 16 to 30 of 200 results for oncology
In development Reference number: GID-TA11502 Expected publication date: 02 December 2026
In development Reference number: GID-TA11519 Expected publication date: 30 September 2026
Artificial intelligence (AI) technologies to help detect prostate cancer on MRI
In development Reference number: GID-HTE10089 Expected publication date: 12 November 2026
Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
In development Reference number: GID-TA11565 Expected publication date: 18 November 2026
In development Reference number: GID-TA11694 Expected publication date: 10 February 2027
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
Percutaneous cementoplasty for palliative treatment of bony malignancies (HTG117)
Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.
View recommendations for HTG117Show all sections
Sections for HTG117
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.
Evidence-based recommendations on laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer. This involves removing the uterus through several small cuts in the abdomen (keyhole surgery), with the aid of an internal telescope and camera.
View recommendations for HTG229Show all sections
Sections for HTG229
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
View recommendations for HTG472Show all sections
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.